SOX2 and lung carcinoma: We have identified that significantly overexpressed LncRNA SOX2‐OT levels in human lung carcinomas (Fig. S5A) are associated to poorer overall survival in lung cancer patients, with lower clinical response to oncological treatments (Cisplatin/Taxanes/EGFR‐TKIs), ranging from 1 to 11 months (Table 1).